After finding the lumen of a needle guide of an ultrasound transducer assembly soiled during patient safety rounds at a VA hospital, the FDA has issued a public health notification about the importance of properly cleaning and sterilizing reusable ultrasound biopsy transducer assemblies and guidelines for doing so.
After finding the lumen of a needle guide of an ultrasound transducer assembly soiled during patient safety rounds at a VA hospital, the FDA has issued a public health notification about the importance of properly cleaning and sterilizing reusable ultrasound biopsy transducer assemblies and guidelines for doing so.
During a biopsy, the transducer assembly should be covered with a sterile barrier sheath because it is likely to come into contact with blood, other bodily fluids, or feces, according to the FDA alert. Because insertion of the biopsy needle is often repeated through the guide, the needle and needle guide should be reprocessed as critical devices.
The biopsy needle and its containing guide must always be sterilized. This should apply even if a sterile barrier sheath is used on the transducer assemblies during a biopsy procedure, as the sheath is compromised by the penetration of the needle. The device should also be cleaned before sterilization to ensure no residue remains on the needle guide lumens from the previous procedure.
The full notification and guidelines can be viewed at www.fda.gov/cdrh/safety/061906-ultrasoundtransducers.html.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.